Skip to main content
TipRanks
Go Ultimate75% OFF

Revvity (RVTY) Revenue by Segment

578 Followers

Revenue by Segment

In Q3 2026, Revvity reported revenue by segment of $379.59M (Life Sciences) and $349.31M (Diagnostics).

Shows total sales for each business segment, identifying which units drive top‑line growth and how balanced the company’s portfolio is. Faster‑growing segments point to future upside, while slow or shrinking segments may require strategic changes or indicate market saturation.

$0.00$250.00M$500.00M$750.00M$1.00B$1.25BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Diagnostics has been the recovery engine since the 2022 trough — steady, double‑digit organic momentum per the call and strong high‑content instrument orders plus Genomics England contribution — while Life Sciences is choppier, pressured by Signals software contract timing and tough comps. Management's upgraded 2026 outlook and the ACD/Labs tuck‑in support the mid-single-digit organic target, but some of Q2's outperformance was one-time (tariff refunds, tax timing) and sustained margin upside depends on a software rebound and resolving instrument production timing.

RVTY Revenue by Segment

PeriodLife SciencesDiagnostics
Q3 2026Sep 30, 2026$379.59M$349.31M
Q2 2026Jun 30, 2026$358.70M$370.99M
Q1 2026Mar 31, 2026$361.85M$349.27M
Q4 2025Dec 31, 2025$381.99M$390.07M
Q3 2025Sep 30, 2025$342.82M$356.13M
Q2 2025Jun 30, 2025$365.90M$354.39M
Q1 2025Mar 31, 2025$340.39M$324.37M
Q4 2024Dec 31, 2024$336.34M$392.41M
Q3 2024Sep 30, 2024$300.92M$383.33M
Q2 2024Jun 30, 2024$313.85M$378.05M
Q1 2024Mar 31, 2024$303.04M$347.09M
Q4 2023Dec 31, 2023$319.69M$376.42M
Q3 2023Sep 30, 2023$307.86M$363.09M
Q2 2023Jun 30, 2023$336.35M$372.92M
Q1 2023Mar 31, 2023$328.44M$346.63M
Q4 2022Dec 31, 2022$347.43M$393.99M
Q3 2022Sep 30, 2022$312.78M$399.22M
Q2 2022Jun 30, 2022$326.61M$569.23M
Q1 2022Mar 31, 2022$306.09M$657.28M
Q4 2021Dec 31, 2021$654.91M$709.41M
Q3 2021Sep 30, 2021$512.88M$653.80M
Q2 2021Jun 30, 2021$512.83M$715.64M
Q1 2021Mar 31, 2021$454.61M$853.08M

Related KPIs